Tags

Type your tag names separated by a space and hit enter

Effects of obesity and hormone therapy on surgically-confirmed fibroids in postmenopausal women.
Eur J Epidemiol 2015; 30(6):493-9EJ

Abstract

To examine the association between body mass index (BMI), use of menopausal hormone therapy (HT), and incidence of uterine fibroids in postmenopausal women, 610,604 postmenopausal women without prior hysterectomy or diagnosis of fibroids were followed as part of a large United Kingdom prospective cohort study. We used Cox regression models to calculate adjusted relative risks (RRs) of surgically-confirmed fibroids (defined as a hospital admission with uterine fibroids as a primary diagnosis with a related surgical procedure), in relation to BMI and use of HT. During an average of 11.4 years of follow-up, 3561 women were admitted to hospital with surgically-confirmed fibroids. Five-year incidence rates decreased with age, from 0.50% (1 in 200 women) at age 50-54, to 0.11% (1 in 1000 women) at age 75-79. The 5-year rate in postmenopausal women aged 50-54 was about a quarter that seen in premenopausal women of the same age (1 in 200 vs. 1 in 50). Compared with normal weight women, obese women had a RR of surgically-detected fibroids of 1.46 (95% CI 1.33-1.59; p < 0.0001). HT use was associated with a RR of 2.33 (95% CI 2.18-2.49; p < 0.0001) in ever versus never users. When we analysed HT use and BMI together, obese vs. normal weight never users had a RR of 2.00 (95% CI 1.77-2.26): the highest risks were seen in women who were obese and had ever used HT, RR = 3.30 (95% CI 2.88-3.79). Uterine fibroids continue to occur in postmenopausal women; obesity and hormone therapy use are important modifiable risk factors.

Authors+Show Affiliations

Cancer Epidemiology Unit, University of Oxford, Richard Doll Building, Roosevelt Drive, Old Road Campus, Oxford, OX3 7LF, UK, eva.sommer@btinternet.com.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25784364

Citation

Sommer, Eva M., et al. "Effects of Obesity and Hormone Therapy On Surgically-confirmed Fibroids in Postmenopausal Women." European Journal of Epidemiology, vol. 30, no. 6, 2015, pp. 493-9.
Sommer EM, Balkwill A, Reeves G, et al. Effects of obesity and hormone therapy on surgically-confirmed fibroids in postmenopausal women. Eur J Epidemiol. 2015;30(6):493-9.
Sommer, E. M., Balkwill, A., Reeves, G., Green, J., Beral, D. V., & Coffey, K. (2015). Effects of obesity and hormone therapy on surgically-confirmed fibroids in postmenopausal women. European Journal of Epidemiology, 30(6), pp. 493-9. doi:10.1007/s10654-015-0016-7.
Sommer EM, et al. Effects of Obesity and Hormone Therapy On Surgically-confirmed Fibroids in Postmenopausal Women. Eur J Epidemiol. 2015;30(6):493-9. PubMed PMID: 25784364.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of obesity and hormone therapy on surgically-confirmed fibroids in postmenopausal women. AU - Sommer,Eva M, AU - Balkwill,Angela, AU - Reeves,Gillian, AU - Green,Jane, AU - Beral,Dame Valerie, AU - Coffey,Kate, AU - ,, Y1 - 2015/03/18/ PY - 2014/09/26/received PY - 2015/03/04/accepted PY - 2015/3/19/entrez PY - 2015/3/19/pubmed PY - 2015/12/31/medline SP - 493 EP - 9 JF - European journal of epidemiology JO - Eur. J. Epidemiol. VL - 30 IS - 6 N2 - To examine the association between body mass index (BMI), use of menopausal hormone therapy (HT), and incidence of uterine fibroids in postmenopausal women, 610,604 postmenopausal women without prior hysterectomy or diagnosis of fibroids were followed as part of a large United Kingdom prospective cohort study. We used Cox regression models to calculate adjusted relative risks (RRs) of surgically-confirmed fibroids (defined as a hospital admission with uterine fibroids as a primary diagnosis with a related surgical procedure), in relation to BMI and use of HT. During an average of 11.4 years of follow-up, 3561 women were admitted to hospital with surgically-confirmed fibroids. Five-year incidence rates decreased with age, from 0.50% (1 in 200 women) at age 50-54, to 0.11% (1 in 1000 women) at age 75-79. The 5-year rate in postmenopausal women aged 50-54 was about a quarter that seen in premenopausal women of the same age (1 in 200 vs. 1 in 50). Compared with normal weight women, obese women had a RR of surgically-detected fibroids of 1.46 (95% CI 1.33-1.59; p < 0.0001). HT use was associated with a RR of 2.33 (95% CI 2.18-2.49; p < 0.0001) in ever versus never users. When we analysed HT use and BMI together, obese vs. normal weight never users had a RR of 2.00 (95% CI 1.77-2.26): the highest risks were seen in women who were obese and had ever used HT, RR = 3.30 (95% CI 2.88-3.79). Uterine fibroids continue to occur in postmenopausal women; obesity and hormone therapy use are important modifiable risk factors. SN - 1573-7284 UR - https://www.unboundmedicine.com/medline/citation/25784364/full_citation L2 - https://doi.org/10.1007/s10654-015-0016-7 DB - PRIME DP - Unbound Medicine ER -